Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Time to Bet on This Biotech Spinoff?

There hasn’t been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration in 2012. In March 2013, ahead of the vote by the FDA’s advisory committee, there were speculations of a possible takeover by partner GlaxoSmithKline plc (ADR) (NYSE:GSK) on expectations of a positive outcome.

In April 2013 came the announcement that the company’s board had approved the separation of its two businesses into two publicly traded companies. The announcement served to prop up the share price despite unfavorable Q1 2013 results, largely weighed down by a positive one-time item last year.

A spinoff is usually a positive as separation of two disparate assets normally unlocks hidden value in the company. It happens with large companies as well as mid-cap entities. We saw this happen when Abbott Laboratories (NYSE:ABT) spun off its biotech wing into an independent company, AbbVie Inc (NYSE:ABBV). More recently, Elan Corporation, plc (ADR) (NYSE:ELN) spun off its drug discovery business in December 2012. It may not be entirely due to the spinoff but from separation to-date the stock of spun-out Prothena Corporation PLC (NASDAQ:PRTAappreciated 180% while Elan, which was bought by Perrigo Company (NYSE:PRGO) is up, 54%.

Theravance Inc (NASDAQ:THRX)In the case of Theravance Inc (NASDAQ:THRX), it is to be split into two companies with different business models. One company will manage royalty income and commercial responsibilities of partnerships — the collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK) in regard to development of COPD drugs — so as to provide a steady return to investors and the other is to be a focused drug discovery company.

LAMA candidate TD-4208
On Sept. 4, Theravance Inc (NASDAQ:THRX) announced that its long-acting muscarinic antagonist, or LAMA, candidate TD-4208 met primary and secondary endpoints in a phase 2 study, treating patients with moderate to severe COPD.

Asthma and COPD have similar symptoms as they both cause inflammation that limits airflow. The causes are different; asthma is a reversible temporary allergic reaction, and COPD is irreversible due to a combination of lung tissue breaking down. Children with severe cases of asthma are much more likely to develop COPD later in life.

In May, Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK) entered the once-daily COPD market when the FDA approved Breo Ellipta.

LAMA/LABA: Potential and competition
The global market for COPD/asthma treatments was worth $25 billion in 2010 and is expected to grow to $27 billion by 2017.

Long-acting bronchodilators such as LAMA and LABA (long-acting β2-agonist) and combinations of the two have brought about a dramatic change in management of COPD and changed the way the medical industry looks at the disease.  In July 2013, Ultibro Breezhaler from Novartis AG (ADR) (NYSE:NVS) became the first in class of fixed-dose, once-daily LAMA/LABA combination to be recommended for approval by the European regulator for sale in Europe.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.